Completed Cancer NIHR-supported project Lungs & Breathing

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Funder NIHR (part of DHSC)
Recipient organisation NIHR Barts Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Mar 2025 — Dec 2025

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Bernadett Szabados (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy versus BCG alone in High-Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guerin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy.
A Phase 2 Open-label Randomised Study of V940 in Combination With BCG versus BCG Monotherapy in Participants with High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
A phase III, randomised, open label, multicentre, global study of durvalumab and bacillus calmette-guerin (BCG) administered as combination therapy veruss BCG alone in high risk, BCG naive non-muscle-invasive bladder cancer patients [POTOMAC]
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Original classification

Precision Cancer Care

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.